Skip to main content

Advertisement

SpringerLink
Log in

Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Introduction

FAM230B has been characterized as an oncogenic lncRNA in papillary thyroid cancer and gastric cancer, while its role in osteosarcoma (OS) is unclear. This research was conducted to analyze the interaction between FAM230B and miR-302b in OS.

Materials and methods

Paired OS and non-tumor tissues donated by 58 OS patients were subjected to RNA preparation and RT-qPCR to quantify the expression of FAM230B and miR-302b (both mature and premature). The subcellular location of FAM230B and its interaction with premature miR-320b were analyzed by cellular fractionation assay and RNA pull-down assay, respectively. The roles of FAM230B and miR-302b in OS cell movement were evaluated using Transwell assay.

Results

Increased FAM230B and premature miR-302b and decreased mature miR-302b were observed in OS. FAM230B was detected in both nuclear and cytoplasm samples and directly interacted with premature miR-302b. FAM230B overexpression in OS cells 143B and HOS decreased miR-302b maturation and increased cell invasion and migration, while miR-302b overexpression suppressed cell invasion and migration. FAM230B silencing restrained cell invasion and migration, and miR-302b inhibitor accelerated cell invasion and migration. MiR-302b knockdown significantly reversed the suppressive effects of shFAM230B on migration and invasion of 143B and HOS cells.

Conclusion

FAM230B is accumulated to high levels in OS and may serve as an endogenous competing RNA for premature miR-302b in the nucleus to promote OS cell invasion and migration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lindsey BA, Markel JE, Kleinerman ES (2017) Osteosarcoma overview. Rheumatol Ther 4:25–43. https://doi.org/10.1007/s40744-016-0050-2

    Article  PubMed  Google Scholar 

  2. Moreno F, Cacciavillano W, Cipolla M, Coirini M, Streitenberger P, López Martí J, Palladino M, Morici M, Onoratelli M, Drago G, Schifino A, Cores M, Rose A, Jotomliansky J, Varel M, García Lombardi M (2017) Childhood osteosarcoma: incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA network 2000–2013. Pediatr Blood Cancer 64:e26533. https://doi.org/10.1002/pbc.26533

    Article  CAS  Google Scholar 

  3. Taran SJ, Taran R, Malipatil NB (2017) Pediatric Osteosarcoma: an updated review. Indian J Medical Paediatr Oncol 38:33–43. https://doi.org/10.4103/0971-5851.203513

    Article  Google Scholar 

  4. Ługowska I, Pieńkowski A, Szumera-Ciećkiewicz A, Koseła-Paterczyk H, Teterycz P, Głogowski M, Kozak K, Klimczak A, Falkowski S, Rutkowski P (2017) The long-term treatment outcomes of adult osteosarcoma. Pol Merkur Lekarski 42:158–164

    PubMed  Google Scholar 

  5. Tsagozis P, Laitinen MK, Stevenson JD, Jeys LM, Abudu A, Parry MC (2019) Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis. Bone Joint J 101-B:739–744. https://doi.org/10.1302/0301-620x.101b6.Bjj-2018-1090.R1

    Article  CAS  PubMed  Google Scholar 

  6. Yu W, Zhu J, Wang Y, Wang J, Fang W, Xia K, Shao J, Wu M, Liu B, Liang C, Ye C, Tao H (2017) A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep. Oncotarget 8:39833–39848. https://doi.org/10.18632/oncotarget.16243

    Article  PubMed  PubMed Central  Google Scholar 

  7. Nieto-Coronel MT, López-Vásquez AD, Marroquín-Flores D, Ruiz-Cruz S, Martínez-Tláhuel JL, De la Garza-Salazar J (2018) Central nervous system metastasis from osteosarcoma: case report and literature review. Rep Prac Oncol Radiother 23:266–269. https://doi.org/10.1016/j.rpor.2018.06.003

    Article  Google Scholar 

  8. Meazza C, Cefalo G, Massimino M, Daolio P, Pastorino U et al (2017) Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2. Med Oncol (Northwood, London, England) 34:191. https://doi.org/10.1007/s12032-017-1052-9

    Article  CAS  Google Scholar 

  9. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R (2018) Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18:39–50. https://doi.org/10.1080/14737140.2018.1413939

    Article  CAS  PubMed  Google Scholar 

  10. Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG et al (2019) Genome-informed targeted therapy for osteosarcoma. Cancer Discov 9:46–63. https://doi.org/10.1158/2159-8290.Cd-17-1152

    Article  CAS  PubMed  Google Scholar 

  11. Chaiyawat P, Settakorn J, Sangsin A, Teeyakasem P, Klangjorhor J, Soongkhaw A, Pruksakorn D (2017) Exploring targeted therapy of osteosarcoma using proteomics data. Onco Targets Ther 10:565–577. https://doi.org/10.2147/ott.S119993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Liu YJ, Zhou HG, Chen LH, Qu DC, Wang CJ, Xia ZY, Zheng JH (2019) MiR-32-5p regulates the proliferation and metastasis of cervical cancer cells by targeting HOXB8. Eur Rev Med Pharmacol Sci 23:87–95. https://doi.org/10.26355/eurrev_201901_16752

    Article  PubMed  Google Scholar 

  13. Yang G, Lu X, Yuan L (2014) LncRNA: a link between RNA and cancer. Biochim Biophys Acta 11:1097–1109. https://doi.org/10.1016/j.bbagrm.2014.08.012

    Article  CAS  Google Scholar 

  14. Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W (2019) Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res 9:1354–1366

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhou Q, Feng J, Yin S, Ma S, Wang J, Yi H (2021) LncRNA FAM230B promotes the metastasis of papillary thyroid cancer by sponging the miR-378a-3p/WNT5A axis. Biochem Biophys Res Commun 546:83–89. https://doi.org/10.1016/j.bbrc.2021.01.109

    Article  CAS  PubMed  Google Scholar 

  16. Cui Y, Pu R, Ye J, Huang H, Liao D, Yang Y, Chen W, Yao Y, He Y (2020) LncRNA FAM230B promotes gastric cancer growth and metastasis by regulating the miR-27a-5p/TOP2A axis. Dig Dis Sci. https://doi.org/10.1007/s10620-020-06581-z

    Article  PubMed  PubMed Central  Google Scholar 

  17. Xie Y, Sun W, Deng Z, Zhu X, Hu C, Cai L (2017) MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2. Sci Rep 7:13388. https://doi.org/10.1038/s41598-017-13353-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Orthopedics, Central Hospital of Loudi City, Loudi, 417000, Hunan, China

    Shigao Cheng

  2. Department of Orthopedics, Second Xianya Hospital, Central South University, No. Renmin Middle Road, Changsha, 410011, Hunan, China

    Shigao Cheng & Wanchun Wang

Authors
  1. Shigao Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wanchun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shigao Cheng, Wanchun Wang: study concepts, literature research, clinical studies, data analysis, experimental studies, manuscript writing and review; Shigao Cheng, Wanchun Wang: study design, literature research, experimental studies and manuscript editing; Shigao Cheng: definition of intellectual content, clinical studies, data acquisition and statistical analysis; Wanchun Wang: data acquisition, manuscript preparation and data analysis. All authors have read and approved the submission of the manuscript.

Corresponding author

Correspondence to Wanchun Wang.

Ethics declarations

Conflict of interest

All authors have no conflicts of interest.

Consent to publishing

Not applicable.

Consent to participate

All patients signed the written informed consent.

Ethical approval

All procedures were approved by the Ethics Committee of Second Xiangya Hospital and operated in keeping with the standards set out in the Announcement of Helsinki and laboratory guidelines of research in China.

Availability of data materials

The data that support the findings of this study are available on request from the corresponding author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

774_2022_1319_MOESM1_ESM.tif

Supplementary file1 Supplemental Fig.1 Effects of FAM230B knockdown and miR-320b inhibitor on premature (A) and mature (B) miR-302b levels. *, p < 0.05 (TIF 799 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, S., Wang, W. Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma. J Bone Miner Metab 40, 554–560 (2022). https://doi.org/10.1007/s00774-022-01319-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-022-01319-5

Keywords

Search

Navigation